Beckman Coulter Life Sciences, a worldwide chief in laboratory automation and innovation, and an organization of Danaher Company (NYSE: DHR), launches the Cydem VT Automated Clone Screening System, a revolutionary high-throughput microbioreactor platform for automated high clone screening.
The brand new Cydem VT System considerably reduces time to marketplace for biologic drug discovery and monoclonal antibody-based therapeutics, by slashing handbook laboratory steps in Cell Line Growth as much as 90% in a single experiment, and eliminating the necessity for a lot of subsequent conventional screening steps.
By delivering early solutions for cell progress and productiveness within the cell line growth course of, the Cydem VT System supplies labs with extra dependable clones in comparison with conventional strategies, together with higher cultivation circumstances which might be nearer to biomanufacturing manufacturing. The all-in-one high-throughput screening platform is good in cell line growth of Chinese language Hamster Ovary (CHO) cell traces producing monoclonal antibodies (mAbs).
“Our Cydem VT Automated Clone Screening System affords an thrilling revolution to expedite crucial analysis therapies for diseases, together with autoimmune ailments and lots of kinds of most cancers,” stated Product Supervisor Dr. Sebastian Hofzumahaus. “We heard the issues about choosing poor productiveness clones and understood the crucial have to develop an easy-to-use answer that confidently and constantly identifies the very best clones. Via offering early solutions and higher cultivation circumstances, we’re ready to make sure higher accuracy with fewer steps to scale back the danger of dangerous clones to assist laboratories uncover their subsequent massive breakthrough even sooner and positively affect human well being.”
The system combines a number of trusted Beckman Coulter Life Sciences applied sciences together with microbioreactor, liquid dealing with, antibody titer and cell well being (cell rely & viability) measurements into one superior platform that empowers lab managers with a simpler, higher-throughput methodology for high clone screening. It permits parallel pH-controlled, fed-batch cultivation and monitoring of as much as 96 bioreactors with particular person gassing.
Automated operations present a minimum of three days of walk-away time throughout an experiment. On-line, non-invasive pH, dissolved oxygen (DO) and biomass measurements present steady management over crucial cultivation parameters. On-deck dedication of cell focus, viability and titer focus guarantee knowledgeable choice of the highest clones. Study extra in regards to the Cydem VT Automated Clone Screening System by clicking right here.
